NEW YORK – Chinese molecular diagnostics firm Burning Rock Biotech announced Sunday a strategic collaboration with CStone Pharmaceuticals to co-develop and commercialize companion diagnostics for Blueprint Medicines' pralsetinib in China.
NEW YORK – Chinese molecular diagnostics firm Burning Rock Biotech announced Sunday a strategic collaboration with CStone Pharmaceuticals to co-develop and commercialize companion diagnostics for Blueprint Medicines' pralsetinib in China.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.